latent tuberculosis treatment rifampin

BACKGROUND:

A third of the world’s population is infected with tuberculosis, latent tuberculosis treatment rifampin and 9 months of isoniazid monotherapy is the preferred treatment for latent tuberculosis infection.

latent tuberculosis treatment rifampin

However, this approach has been associated with hepatotoxicity and poor compliance. Shorter (4 months) rifampicin therapy has been studied in recent clinical trials.
methods:

A meta-analysis of published studies to evaluate the toxicity compare performance and cost-effectiveness between the two strategies implemented. Combination effects were calculated as risk (RR) by random effects and fixed-effects models.
RESULTS:

latent tuberculosis treatment rifampin

Combined data from 3586 patients suggest that treatment with rifampicin was associated with a significant reduction in the risk of non-completion (RR for the random effects model, 0.53, 4 months, associated 95% confidence interval [CI]: 0 , 44 to 0.63). Fees, 4 months (range, 8.6% -28.4%) were not completed lower in patients rifampicin treated compared to non-completion rates in patients with isoniazid for 9 months (range, 24.1% -47 , 4%). In addition, the rates of hepatotoxicity (as the failure of grade 3 or 4 liver, the discontinuation of treatment defined) lower in patients rifampicin 4 months (range 0% -0.7%) compared were patients isoniazid for 9 months (range 1.4% -5.2%), rifampicin, and was associated with a significant reduction in the risk of liver toxicity (RR model for solid, 0.12, 95% CI, 0.05 to 0, 30 connected) effects. In particular, the data from our meta-analysis, it was estimated that four months rifampicin strategy is also cost effective and lead to a $ 213 savings per patient treated ($ 90/patient when treatment costs not included).
CONCLUSION:

The improved compliance, safety, and cost, the suspect connected with rifampicin four months study that the effectiveness of this approach should be evaluated in detail. A comprehensive post-treatment follow-up studies will be clarified in the future. latent tuberculosis treatment rifampin The unresolved question of the rates of reactivation of tuberculosis

StatPress

Visits today: 13